Subchronic oral toxicity of salcaprozate sodium (SNAC) in sprague-dawley and wistar rats

International Journal of Toxicology

Volumn 28, Issue 4, 2009, Pages 278-293

  Riley, M Gary I ^a   Castelli, M Cristina ^a   Paehler , Ellen Angela ^b  

^a Emisphere Technologies   (United States)

^b Harlan   (Switzerland)

Author keywords

CAS RN 203787 91 1; Rat; Salcaprozate sodium; SNAC; Subchronic toxicity

Indexed keywords

OCTANOIC ACID; SALCAPROZATE SODIUM; SERUM GLOBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC TOXICITY; ELECTROLYTE BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; KIDNEY MASS; LIVER WEIGHT; MALE; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; CAPRYLATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FEMALE; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SPECIES SPECIFICITY;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 71549163809     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581809337737     Document Type: Article

References (8)

1. Baughman RA, Kapoor SC, Agarwal RK, Kisicki J, Catella- Lawson F, Fitzgerald GA. Oral delivery of anticoagulant doses of heparin: a randomized, double-blind, controlled study in humans. Circulation. 1998;98:1610-1615.
2. Abbas R, Osgood G, Rivera-Schaub T, Kisicki JC, Baughman RA. A clinical drug-interaction study to evaluate the effect of antacid pretreatment on the absorption of heparin and its delivery agent, SNAC, following oral administration in healthy subjects. AAPS PharmSci. 2001;3(S1). http://www.aapspharmsci.org/.
3. Abbas R, Agarwal R, Rivera-Schaub T, Leone-Bay A, Chaudhary K, Baughman RA. Evaluation of the effect of three different oral heparin/SNAC formulations on pharmacokinetics (PK) of heparin following oral administration in healthy subjects. AAPS PharmSci. 2002;4(S1). http://www.aapspharmsci.org/.
4. Berkowitz SD, Marder VJ, Kosutic G, Baughman RA. Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. J Thromb Haemost. 2003; 1:1914-1919.
5. Kidron M, Dinh S, Menachem Y, et al. A novel per-oral insulin formulation: proof of concept study in nondiabetic subjects. Diabetes Med. 2004;21:354-357.
6. Mousa SA, Zhang F, Aljada A, et al. Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects. J Clin Pharmacol. 2007;47: 1508-1520.
7. Leone-Bay A, Leipold H, Agarwal R, Rivera T, Baughman RA. The evolution of an oral heparin dosing solution. Drugs Future. 1997;22:885-891.
8. Proctor DM, Gatto NM, Hong SJ, Allamneni KP. Modeof- action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment. Toxicol Sci. 2007;98:313-326.